At the recent European Alliance of Associations for Rheumatology (EULAR) 2024 conference, chimeric antigen receptor (CAR) T-cell modalities in autoimmune diseases, including systemic lupus erythematosus (SLE) and lupus nephritis (LN), was featured as a key topic.

This modality’s potential to achieve drug-free remission in patients with autoimmune diseases such as SLE and LN is a key focus that pharma companies continue to explore.

The results presented at EULAR 2024 from ongoing, industry-sponsored, early-stage clinical trials generally gave early indications that CAR T-cell assets may be able to achieve an immune reset and potentially help patients achieve drug-free remission.

However, reports of relapse post-infusion have drawn cautious optimism about an otherwise promising display of results for CAR T-cell assets in this disease space.

Achieving drug-free remission would represent a transformative, paradigm-shifting moment in the care of patients with SLE and LN.

Results from ongoing clinical trials indicate a movement in the right direction for CAR T-cell assets in SLE and LN.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

View profiles in store

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Submit

UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo

Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital

Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.

Submit and download

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Kyverna Therapeutics’ KYV-101 exhibited disease control at a follow-up period, with six of the seven patients with LN not requiring immunosuppressants and two of these patients having completed at least six months post-infusion.

Results from Cabaletta Bio’s CABA-201 RESET-SLE trial indicated an improvement in the SLE Disease Activity Index 2000 score and resolution of vasculitis, arthritis, and haematuria within four weeks post-infusion in one patient with SLE, with ongoing taper from prednisone 10mg per day.

Preliminary data from JW Therapeutics’ JWCAR029 also suggested efficacy, with three patients in the low-dose group showing a reduction in Safety of Estrogens in Lupus Erythematosus National Assessment–SLEDAI scores at four months follow-up.

Additionally, all three patients achieved SLE responder index-4 while two patients reached lupus low disease activity status.

iCell Gene Therapeutics’ BCMA CD19 compound CAR T cells also delivered promising results that demonstrated SLE patients free of lupus medication at a mean follow-up period of 20 months and in LN patients at a mean follow-up period of 16 months.

While the general sentiment over these results has been positive, episodes of relapses among patients have generated caution, including in the case of one patient who received KYV-101 and relapsed five months post-infusion.

According to leading data and analytics company GlobalData’s Pharmaceutical Intelligence Center, of the 18 CAR T-cell assets currently in pipeline clinical development for SLE/LN, 50% of pipeline assets are being evaluated in China (Table 1).

This trend indicates the emergence of China as a leader in the development of CAR T-cell therapies within the autoimmune disease space.

The trend also highlights the opportunity for large pharma companies to partner with companies conducting clinical trials in China to propel the growth of the CAR T-cell modality on a broader geographical scale.

Clinical developments and commercial partnerships within the CAR T-cell space will be crucial to meet the unmet needs that exist within the SLE and LN disease spaces.

Key opinion leaders interviewed by GlobalData have emphasised the need for agents that can help patients, especially those with refractory forms of the disease, into remission without the need for these patients to be on traditional steroid and immune-suppressive therapies.

As these innovator modalities continue along the path of development, clinical milestones achieved during this process will be seen as key moments that will propel the growth of this market.